Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The possibility that history of depression is a risk factor for dementia needs to be taken seriously and explanations of the association need to be further researched. 2 key findings →

Design: meta-analysis Evidence: high

The relationships between total serum cholesterol (TC) and dementia and between TC and cognitive decline were investigated in a systematic review of 18 prospective studies. 5 key findings →

Design: systematic review Participants: 14,331 Evidence: high

The search for biomarkers as a diagnostic aid to the identification of patients in pre-dementia stages is a fast growing research area. 1 key finding →

Design: systematic review Participants: 123 Evidence: high

Social support interventions for caregivers of older adults with dementia: a scoping review

✓ Peer-reviewed alzhub usefulness score 61 out of 100. BMJ Open 2025-06-01

A total of 31 studies were selected for this review, revealing six distinct categories of social support interventions for caregivers of older adults with dementia. 5 key findings →

Design: meta-analysis Participants: 31 Evidence: high

Mary Poppins famously asserted that "a spoonful of sugar helps the medicine go down," but this bon mot is likely wrong in almost every way. 1 key finding →

Design: meta-analysis Participants: 74,148 Evidence: high

The global metabolic disorder, type 2 diabetes mellitus (T2DM), significantly increases the risk of cognitive dysfunction, including Alzheimer's disease (AD) and mild cognitive impairment (MCI). 5 key findings →

Design: meta-analysis Participants: 250,000 Evidence: high

People with type 2 diabetes mellitus (T2DM) are at increased risk of mild cognitive impairment and dementia. 5 key findings →

Design: meta-analysis Evidence: high

Rare coding variants in TREM2, PLCG2, and ABI3 were recently associated with the susceptibility to Alzheimer's disease (AD) in Caucasians. 2 key findings →

Design: meta-analysis Evidence: high

The loss of occlusal support may lead to cognitive dysfunction through the reduction of chewing-related stimuli, aggravation of nerve damage, and long-term inflammatory stress. 1 key finding →

Design: systematic review Participants: 1,317 Evidence: high

The analysis included 26 original articles describing (1050 rodents) with AD-like symptoms. 5 key findings →

Design: systematic review Participants: 26 Evidence: high

This meta-analysis pooled 84 studies comparing family caregivers to demographically similar non-caregivers on stress, depression, well-being, physical health, and self-efficacy. 3 key findings →

Design: meta-analysis Evidence: high

In this review, the evidence that single clinically defined cardiovascular risk factors are significantly associated with incident AD is inconsistent at best. 2 key findings →

Design: systematic review Evidence: high

Danggui-Shaoyao-San for dementia: A PRISMA-compliant systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Medicine 2020-01-01

These estimates suggest that DSS provides clinically important reductions in symptoms of AD and VD and can be a promising anti-dementia drug candidate. 5 key findings →

Design: systematic review Participants: 567 Evidence: high

Physical exercise, aerobic exercise in particular, benefits global cognition in MCI patients. 5 key findings →

Design: systematic review Evidence: high

The evidence is not conclusive as to whether some symptoms are more important than others. 3 key findings →

Design: systematic review Evidence: high

Although multi-component social support interventions may improve caregiver well-being, there is insufficient evidence to conclude whether a change in social support is the underlying mediating factor. 3 key findings →

Design: systematic review Evidence: high

A meta-analysis of 27 primary studies was conducted to examine the relationship between neuropsychological functioning and driving ability for adults with dementia. 2 key findings →

Design: meta-analysis Evidence: high

When assessed by simple questions, SMC appear to be present in the minority of those with mild cognitive impairment and dementia. 3 key findings →

Design: meta-analysis Evidence: high

Further studies should bridge the gap in understanding and give a more global portrait by adding important personal variables such as dementia, organizational variables such as use of community and primary care, and contextual variables such as social and economic frailty. 5 key findings →

Design: systematic review Evidence: high

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed